Recent Highlights

OmniaBio Inc. Awarded Drug Establishment License (DEL) by Health Canada, Certifying Canada’s Largest Cell & Gene Therapy CDMO

HAMILTON & TORONTO ONTARIO – December 23, 2025 – OmniaBio Inc., Canada’s largest cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), today announced that Health Canada has awarded the company a Drug Establishment License (DEL), confirming the maturity and compliance of its Good Manufacturing Practices (GMP).    Secured less than one year after opening the Hamilton, […]

OmniaBio Inc. Awarded Drug Establishment License (DEL) by Health Canada, Certifying Canada’s Largest Cell & Gene Therapy CDMO Read More »

OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer

TORONTO, ONTARIO & BOSTON, MA – October 1st, 2025 – OmniaBio Inc., a next generation contract development and manufacturing organization (CDMO) pioneering the manufacturing of cell and gene therapies (CGT) with robotics and artificial intelligence, and BrainChild Bio Inc, a clinical-stage biotechnology company developing Chimeric Antigen Receptor T-cell (CAR-T) therapies to treat solid tumors in

OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer Read More »

Scroll to Top